Strata Skin Sciences (SSKN)
(Delayed Data from NSDQ)
$0.51 USD
-0.01 (-2.78%)
Updated Apr 26, 2024 03:59 PM ET
After-Market: $0.51 0.00 (-0.87%) 7:10 PM ET
4-Sell of 5 4
C Value B Growth F Momentum C VGM
Balance Sheet
Fiscal Year End for Strata Skin Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 8 | 7 | 13 | 18 | 16 |
Receivables | 4 | 4 | 3 | 3 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 3 | 6 | 3 | 3 | 3 |
Other Current Assets | 0 | 1 | 0 | 0 | 1 |
Total Current Assets | 16 | 18 | 20 | 25 | 24 |
Net Property & Equipment | 12 | 8 | 7 | 6 | 5 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 14 | 26 | 19 | 15 | 17 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 42 | 52 | 47 | 47 | 47 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 7 | 7 |
Accounts Payable | 3 | 3 | 3 | 3 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 1 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 7 | 6 | 5 | 5 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 3 | 3 | 2 | 3 |
Total Current Liabilities | 12 | 13 | 13 | 19 | 17 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 1 | 1 | 1 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 15 | 7 | 7 | 1 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 1 | 8 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 29 | 30 | 21 | 21 | 19 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 251 | 249 | 247 | 245 | 243 |
Retained Earnings | -238 | -227 | -222 | -219 | -215 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 13 | 22 | 25 | 26 | 29 |
Total Liabilities & Shareholder's Equity | 42 | 52 | 47 | 47 | 47 |
Total Common Equity | 13 | 22 | 25 | 26 | 29 |
Shares Outstanding | 34.70 | 34.70 | 34.30 | 33.70 | 32.90 |
Book Value Per Share | 0.37 | 0.63 | 0.74 | 0.77 | 0.87 |
Fiscal Year End for Strata Skin Sciences, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 8 | 8 | 10 | 4 |
Receivables | NA | 4 | 5 | 4 | 4 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 3 | 6 | 6 | 6 |
Other Current Assets | NA | 0 | 0 | 1 | 1 |
Total Current Assets | NA | 16 | 20 | 21 | 15 |
Net Property & Equipment | NA | 12 | 8 | 8 | 8 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 14 | 18 | 25 | 25 |
Deposits & Other Assets | NA | 0 | 0 | 0 | 0 |
Total Assets | NA | 42 | 47 | 55 | 49 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 3 | 3 | 4 | 3 |
Current Portion Long-Term Debt | NA | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 6 | 6 | 7 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 2 | 3 | 3 | 3 |
Total Current Liabilities | NA | 12 | 12 | 14 | 13 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 1 | 1 | 1 | 1 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 15 | 15 | 15 | 8 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 3 | 8 | 8 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 29 | 31 | 38 | 30 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 251 | 250 | 250 | 249 |
Retained Earnings | NA | -238 | -234 | -233 | -230 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 13 | 16 | 17 | 19 |
Total Liabilities & Shareholder's Equity | NA | 42 | 47 | 55 | 49 |
Total Common Equity | 0 | 13 | 16 | 17 | 19 |
Shares Outstanding | 35.00 | 34.70 | 34.90 | 34.80 | 34.80 |
Book Value Per Share | 0.00 | 0.37 | 0.46 | 0.49 | 0.56 |